Saturday - May 16, 2026
Enhertu Approved in the U.S. for Two New Indications for Patients With HER2-Positive Early Breast Cancer
May 16, 2026
WILMINGTON, Delaware, May 16 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Approved for use before surgery based on DESTINY-Breast11 Phase III trial

Approved for use following surgery based on DESTINY-Breast05 Phase III trial

Two new indications bring A . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products